Anton Stuetz

Biography

 , Ph.D. has been Executive Director of Dermatology in Novartis until 2013. Dr. Stuetz studied chemistry and physics at the University of Vienna 1965 –1972 and has a Ph.D. in Organic Synthesis and a postdoc in molecular biology from the Max Planck Institute. Dr. Stuetz subsequently joined the Sandoz Research Institute where he developed the topical anti-infective medicament terbinafine (Lamisil®). Lamisil is today’s golden standard for oral and topical treatment of skin and nail fungal infections. Furthermore, Lamisil has achieved accumulated sales of >10 B USD. In 1986 Dr. Stuetz established the Dermatology Research Department within the Sandoz Research Institute. Here he developed tacrolimus (Protopic®) and pimecrolimus (Elidel®) who were the first two therapeutically effective and registered non-steroids topical treatments against atopic dermatitis. In 1994 Dr. Stuetz was appointed professor of pharmaceutical chemistry at the University of Vienna. He is the author/co-author of 92 publications, 176 abstracts and 35 patents. In 2004 Dr. Stuetz received the ‘Erwin Schroedinger Preis’ by Austria´s Academy of Sciences and he served as a member of the Board of Directors of the Society for Investigative Dermatology from 2005-2010. In 2011 Dr. Stuetz received the prestigious ‘Eugene J. Van Scott Award’ for Innovative Therapy of the Skin and the ‘Philipp Frost Leadership Lecture’ by the American Academy of Dermatology

Research Interest

management